CN115175686A - 用于增强嵌合t细胞持久性的akt抑制剂 - Google Patents

用于增强嵌合t细胞持久性的akt抑制剂 Download PDF

Info

Publication number
CN115175686A
CN115175686A CN202080093576.0A CN202080093576A CN115175686A CN 115175686 A CN115175686 A CN 115175686A CN 202080093576 A CN202080093576 A CN 202080093576A CN 115175686 A CN115175686 A CN 115175686A
Authority
CN
China
Prior art keywords
car
cells
cell
domain
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080093576.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·L·达维拉
S·M·塞卜蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lee Moffitt Cancer Center and Research Institute Inc
Original Assignee
H Lee Moffitt Cancer Center and Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Center and Research Institute Inc filed Critical H Lee Moffitt Cancer Center and Research Institute Inc
Publication of CN115175686A publication Critical patent/CN115175686A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080093576.0A 2019-11-18 2020-11-18 用于增强嵌合t细胞持久性的akt抑制剂 Pending CN115175686A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962937028P 2019-11-18 2019-11-18
US62/937,028 2019-11-18
US201962937359P 2019-11-19 2019-11-19
US62/937,359 2019-11-19
US201962942662P 2019-12-02 2019-12-02
US62/942,662 2019-12-02
US201962944295P 2019-12-05 2019-12-05
US62/944,295 2019-12-05
US202062982480P 2020-02-27 2020-02-27
US62/982,480 2020-02-27
PCT/US2020/061107 WO2021102038A1 (en) 2019-11-18 2020-11-18 Akt inhibitors for enhancing chimeric t cell persistence

Publications (1)

Publication Number Publication Date
CN115175686A true CN115175686A (zh) 2022-10-11

Family

ID=75981019

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080093576.0A Pending CN115175686A (zh) 2019-11-18 2020-11-18 用于增强嵌合t细胞持久性的akt抑制剂

Country Status (11)

Country Link
US (1) US20230039099A1 (https=)
EP (1) EP4061383A4 (https=)
JP (1) JP2023503061A (https=)
KR (1) KR20220130100A (https=)
CN (1) CN115175686A (https=)
AU (1) AU2020387407A1 (https=)
BR (1) BR112022009607A2 (https=)
CA (1) CA3162094A1 (https=)
IL (1) IL293094A (https=)
MX (1) MX2022005973A (https=)
WO (1) WO2021102038A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116390734A (zh) * 2020-09-25 2023-07-04 中国科学院动物研究所 增强t细胞功能的化合物和方法
CN118956769A (zh) * 2024-10-15 2024-11-15 深圳泰华赛尔生物科技有限公司 一种提高car-t细胞功能的培养基及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4340852A4 (en) * 2021-05-19 2025-05-07 Prescient Therapeutics Ltd METHODS FOR PRODUCING ENHANCED IMMUNE CELL POPULATIONS
CN113943710B (zh) * 2021-09-17 2023-03-24 浙江大学医学院附属第一医院 一种car-t细胞培养用的培养基及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070395A1 (en) * 2015-10-20 2017-04-27 Kite Pharma, Inc. Methods of preparing t cells for t cell therapy
WO2017099712A1 (en) * 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
WO2018018958A1 (en) * 2016-04-22 2018-02-01 Carsgen Therapeutics Co., Ltd. Compositions and methods of cellular immunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005024042A2 (en) * 2003-09-04 2005-03-17 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
RU2018105118A (ru) * 2015-08-21 2019-09-23 Пфайзер Инк. Терапевтические наночастицы, содержащие терапевтический агент, и способы их получения и применения

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070395A1 (en) * 2015-10-20 2017-04-27 Kite Pharma, Inc. Methods of preparing t cells for t cell therapy
WO2017099712A1 (en) * 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
WO2018018958A1 (en) * 2016-04-22 2018-02-01 Carsgen Therapeutics Co., Ltd. Compositions and methods of cellular immunotherapy
CN109414512A (zh) * 2016-04-22 2019-03-01 科济生物医药（上海）有限公司 用于细胞免疫疗法的组合物和方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARBARA SAVOLDO等: "CD28 costimulation improves expansion and persistence of chimeric antigen receptor– modified T cells in lymphoma patients", 《THE JOURNAL OF CLINICAL INVESTIGATION》, vol. 121, no. 5, 31 May 2011 (2011-05-31), pages 1822 - 1826, XP055204919, DOI: 10.1172/JCI46110 *
QING ZHANG等: "Akt inhibition at the initial stage of CAR-T preparation enhances the CAR-positive expression rate, memory phenotype and in vivo efficacy", AM J CANCER RES, vol. 9, no. 11, 15 November 2019 (2019-11-15), pages 2380, XP055727366 *
师丽晓等: "PI3k/Akt/mTOR信号通路与儿童急性T淋巴细胞白血病", 《中国实验血液学杂志》, vol. 24, no. 04, 20 August 2016 (2016-08-20), pages 1269 - 1274 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116390734A (zh) * 2020-09-25 2023-07-04 中国科学院动物研究所 增强t细胞功能的化合物和方法
CN118956769A (zh) * 2024-10-15 2024-11-15 深圳泰华赛尔生物科技有限公司 一种提高car-t细胞功能的培养基及其应用

Also Published As

Publication number Publication date
EP4061383A4 (en) 2024-03-27
EP4061383A1 (en) 2022-09-28
WO2021102038A1 (en) 2021-05-27
MX2022005973A (es) 2022-09-09
JP2023503061A (ja) 2023-01-26
CA3162094A1 (en) 2021-05-27
AU2020387407A1 (en) 2022-07-07
US20230039099A1 (en) 2023-02-09
BR112022009607A2 (pt) 2022-10-18
KR20220130100A (ko) 2022-09-26
IL293094A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
US11976121B2 (en) CD123-binding chimeric antigen receptors
KR20200027508A (ko) 돌연변이된 cd28 공동자극 도메인을 갖는 키메라 항원 수용체
JP7252651B2 (ja) Ｃｄ３３発現がんを標的とするための組成物および方法
JP2021509817A (ja) Ｃｌｅｃ１２ａ発現癌を標的にするための組成物および方法
JP2025028959A (ja) 抗原特異的ｃｄ１９標的化ｃａｒ－ｔ細胞
US12077598B2 (en) Chimeric antigen receptors with mutated CD28 phosphorylation sites
JP2021500859A (ja) Ｎｆｋｂシグナル伝達の増強を伴うキメラ抗原受容体
JP2021509816A (ja) Ｃｄ９９−発現癌を標的にするための組成物および方法
CN115175686A (zh) 用于增强嵌合t细胞持久性的akt抑制剂
US20230235067A1 (en) SSTR-2 Binding Chimeric Antigen Receptors
JP2021520780A (ja) Ｎｋｇ２ｄキメラ抗原受容体
US20230051885A1 (en) Systems and Methods for Producing Efficacious Regulatory T Cells
JP2024505184A (ja) Ｂ細胞悪性腫瘍に対する二重特異性ｃａｒ ｔ細胞
JP2024510184A (ja) 治療用ｔ細胞毒性を減少させるための組成物および方法
US20230025160A1 (en) Car t cells with enhanced metabolic fitness
US20250387432A1 (en) Sstr-binding antibodies and chimeric antigen receptors
US20250302878A1 (en) Nkg2d expressing car-t cells
US12156888B2 (en) CAR T-cells for the treatment of bone metastatic cancer
WO2025222119A1 (en) Gp6d overexpression in cellular immunotherapies
RU2800922C2 (ru) Химерные антигенные рецепторы с мутированными костимуляторными доменами cd28
CN119768422A (zh) 具有nk受体信号传导结构域的嵌合抗原受体(car)构建体
WO2025151610A1 (en) Bcl-xl variants for enhancing cellular immunotherapy function
WO2023225641A2 (en) Compositions and methods for targeting clec12a-expressing cancers
HK40064393A (en) Antigen specific cd19-targeted car-t cells
HK40037085A (en) Compositions and methods for targeting clec12a-expressing cancers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221011